GlycoNex Total Liabilities
GlycoNex total liabilities. Based on the latest financial reports, GlycoNex (4168) has total liabilities worth NT$542.22 Million TWD (≈ $17.08 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GlycoNex liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GlycoNex (2017–2024)
Total liabilities of GlycoNex from 2017 to 2024. This chart illustrates how GlycoNex's total liabilities have evolved over time, based on quarterly financial data.
GlycoNex Competitors by Total Liabilities
The table below lists competitors of GlycoNex ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metrofile
JSE:MFL
|
South Africa | ZAC895.00 Million |
|
OFX Group Ltd
AU:OFX
|
Australia | AU$514.38 Million |
|
Cemtas Celik Makina Sanayi ve Ticaret AS
IS:CEMTS
|
Turkey | TL2.44 Billion |
|
Pinetree Capital Ltd
TO:PNP
|
Canada | CA$14.19 Million |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
USA | $117.43 Million |
|
Tonymoly Co Ltd
KO:214420
|
Korea | ₩106.53 Billion |
|
Oxford Square Capital Corp
NASDAQ:OXSQ
|
USA | $155.78 Million |
|
Eco World International Bhd
KLSE:5283
|
Malaysia | RM217.79 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down GlycoNex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of GlycoNex.
Liquidity & Leverage Metrics
GlycoNex Total Liabilities Ratios Explained
GlycoNex total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlycoNex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlycoNex (2017–2024)
The table below shows the annual total liabilities of GlycoNex from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$270.01 Million ≈ $8.51 Million |
-2.31% |
| 2023-12-31 | NT$276.40 Million ≈ $8.71 Million |
+1.87% |
| 2022-12-31 | NT$271.34 Million ≈ $8.55 Million |
+652.25% |
| 2021-12-31 | NT$36.07 Million ≈ $1.14 Million |
+4.65% |
| 2020-12-31 | NT$34.47 Million ≈ $1.09 Million |
+9.91% |
| 2019-12-31 | NT$31.36 Million ≈ $987.98K |
+6.84% |
| 2018-12-31 | NT$29.35 Million ≈ $924.69K |
+16.53% |
| 2017-12-31 | NT$25.19 Million ≈ $793.53K |
-- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more